MEDPACE

RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS

Experts. Experience. Execution.



Experts:

- Seasoned medical, regulatory and clinical project teams with extensive experience designing and conducting Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) trials
- In-house Clinical Immunologist with a background in experimental immunology, molecular biology, and immunogenetics with 13+ years of industrial experience in portfolio management, biomarker development, translational medicine, and development experience in the inflammatory and respiratory disease areas
- A cross-functional team of experts in related indications such as Respiratory Disease, Cardiovascular Disease, and Dermatology brings scientific, operational and regulatory experience and know-how to orchestrate complex studies

Experience:

- Medpace has recent and relevant experience in RA for Phases I-III
- Experienced team with highly relevant operational know-how and subject-matter expertise
- Experience working with biosimilars, combination therapies, and new approaches including immunomodulatory biologics, selective kinase therapies, monoclonal microbial immunomodulation, genetically altered cell therapies as well as gene transfer-mediated immunotherapies

Execution:

- Medpace's scientifically-driven, therapeutically-focused operational model provides cross-collaboration and insights from various medical perspectives
- Strong relationships with key industry investigative sites and key opinion leaders (KOLs)
- Anticipate challenges and proactively navigate rapidly evolving regulations, operational complexities, and tight timelines
- Integrated central lab and imaging core lab for seamless clinical development

Supporting RA and PsA Clinical Research

Whether you need support at the planning stage of your trial (Pre/Post IND) or starting First In Human trials, Medpace has recent and relevant global experience providing you with valuable connections into our KOL network and deeply seated site relationships.

Importantly, Medpace is able to converge our in-house medical experts across many therapeutic areas including Cardiovascular Disease, Respiratory Disease and Dermatology to consult on the most effective and efficient study design.

As an added value, in collecting quality data at an accelerated rate, Medpace trials are supported by our in-house Imaging Core Lab and our global central laboratory providing safety testing and biomarker support.

Medpace: A Full-Service Approach to Accelerate Development

For more than 25 years, Medpace has steadfastly held to a model of providing full-service clinical development services to accelerate the development of safe and effective medical therapeutics. We partner to guide you through the fastest path to commercial success with hands-on and highly-qualified medical, regulatory and operational experts.

Medpace specializes in partnering with biotechnology companies who are developing novel approaches – which are often challenging and complex studies.

Key differentiators for RA and PsA include:

- Recent and relevant Phase I-III global experience
- Experience supporting biosimilars, combination therapies, and new approaches such as:
  - Immunomodulatory biologics
  - Genetically altered cell therapies
  - Gene transfer-mediated immunotherapies
  - Monoclonal microbial immunomodulation
  - Selective Kinase Inhibitors
- Cross-over medical expertise in Cardiovascular Disease, Respiratory Disease and Dermatology
- Specialized in partnering with biotechnology companies who are developing novel approaches; which are often challenging and complex studies
- A well-profiled network of high-producing sites enables timely enrollment and high-quality conduct of trials
- CRO and imaging integration - imaging expertise and clinical trial experience ensures that imaging components are seamlessly integrated into the complex structure of the overall trial. Notably, we use a web-based image management system used to analyze CT and MRI scans for confirmation of eligibility, safety and efficacy evaluations
- Our wholly-owned central laboratory—with locations in the US, Europe, China and Singapore—offers a menu of validated biomarkers associated with RA/PsA with the ability to rapidly establish and validate novel assays as needed
- Flexible, highly-customizable ePRO solution that is fully-integrated into ClinTrak®, Medpace's proprietary data management system

In-House Medical Expertise – Scientifically-driven Clinical Development

Medpace is unique in its scientifically-driven approach to clinical research. The Medpace model gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Our highly experienced medical doctors work closely with our regulatory and operations experts to provide strategic direction for study design and planning, train operational staff, work with Investigators, provide medical monitoring, and meet with regulatory agencies. They are embedded throughout your studies, providing greater depth and the ability to tackle complex and challenging diseases.

Our RA/PsA studies are led by Richard Kay MBChB PhD. Dr. Kay has expertise in RA, as well as long-standing relationships with key opinion leaders (KOLs) and global Principal Investigators (PIs).

Dr. Kay is a Clinical Immunologist with a background in experimental immunology, molecular biology, and immunogenetics. Before joining Medpace, he worked in Global Medical Director roles at both AstraZeneca and Novartis. He has over 13 years of industrial experience in portfolio management, biomarker development, translational medicine, and later development experience in the inflammatory and respiratory disease areas.

Who We Are

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective.